Skip to content
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Gynecology · Uterine Fibroids

Do Uterine Fibroids Run in Families? Screening Advice

At a Glance

Uterine fibroids are more common among close biological relatives, but most symptom-free family members do not need routine ultrasound. New symptoms should prompt medical evaluation, while early, numerous fibroids, painful skin bumps, or young-onset kidney cancer may warrant counseling for rare HLRCC.

Yes, uterine fibroids do tend to run in families, meaning your biological sisters and daughters may have a higher chance of developing them [1] [2]. However, because fibroids are very common and most do not cause symptoms, routine screening for relatives who feel fine is generally not recommended [3] [4].

Here is a closer look at the family connection, when medical evaluation makes sense, and what symptoms your loved ones should watch for.

The Family Connection

Research shows that familial clustering—when a condition appears in multiple members of the same family—is common with uterine fibroids [1]. If you have a first-degree relative (a mother, sister, or daughter) with fibroids, your odds of developing them are higher [2].

However, familial risk means the chances are increased, not certain. Furthermore, fibroids are incredibly common overall. Depending on a person’s age, ancestry, and whether imaging is used to look for silent tumors, studies estimate that up to 70% to 80% of women will develop fibroids by age 50 [5] [3]. Because they are so widespread, having fibroids in your family does not necessarily mean you have a rare inherited genetic disorder [3]. For most people, fibroids are caused by a complex mix of genetic susceptibility, hormones, and environmental factors rather than a single gene passed down through generations [6] [1].

Should My Sister or Daughter Get Screened?

If your sisters or daughters do not have any symptoms, there is no routine ultrasound screening program for them, even with a family history [3] [4].

Medical guidelines recommend against routine imaging for asymptomatic fibroids [3]. Many fibroids are asymptomatic and do not require treatment or intervention [7]. Because discovering “silent” fibroids usually does not change a person’s medical care, routine screening often leads to unnecessary medical tests and anxiety rather than improved health outcomes [4].

Note: Skipping fibroid screening does not mean skipping ordinary preventive care. Your relatives should continue with their routine gynecological visits, recommended cervical cancer screenings, and general wellness checks.

When to Seek Medical Evaluation

Instead of pursuing preemptive imaging, your relatives should pay attention to their bodies and seek medical evaluation if they develop symptoms. Fibroid symptoms generally affect menstruation, pelvic comfort, and the urinary or digestive systems [7] [8].

Your relatives should talk to a doctor if they experience:

  • Abnormal Menstrual Bleeding: Heavy or prolonged periods (such as bleeding that lasts more than seven days or involves large clots), or bleeding between cycles [7] [9].
  • Signs of Iron Deficiency and Anemia: Prolonged heavy bleeding can lead to iron deficiency and anemia (low hemoglobin). This can cause unusual weakness, dizziness, or fatigue [7] [10].
  • Pelvic or Back Pain: A feeling of heavy pressure in the pelvis, frequent pelvic pain, or unexplained lower back pain [8] [11].
  • Urinary and Bowel Changes: Having to urinate frequently, difficulty completely emptying the bladder, or sudden ongoing constipation [8] [12].
  • Fertility Challenges: Difficulty getting pregnant, recurrent miscarriages, or unexplained pregnancy complications [13] [14]. It is important to note that many people with fibroids become pregnant normally; fertility effects depend heavily on a fibroid’s size and whether it distorts the uterine cavity [13].

Remember: These symptoms have many possible causes, so evaluation is highly individualized [7]. A doctor may recommend a pregnancy test, a blood count for anemia, a pelvic exam, or an ultrasound (which can be done abdominally or transvaginally) to determine the actual cause [4] [15].

When to Seek Urgent Care

While most fibroid symptoms are evaluated during routine appointments, some require prompt or urgent medical attention [7] [9]. Seek immediate care for:

  • Severe bleeding: Soaking through a pad or tampon every hour for more than two hours in a row.
  • Severe anemia symptoms: Fainting, marked light-headedness, shortness of breath, chest pain, or a racing heartbeat.
  • Sudden, severe pelvic pain.
  • Any vaginal bleeding during pregnancy.
  • Any vaginal bleeding after menopause (postmenopausal bleeding).

A Rare Exception: HLRCC Genetic Syndrome

While ordinary fibroids are common, there is a rare inherited condition called Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) [16]. Caused by a mutation in the FH gene, HLRCC involves a high risk of both uterine fibroids and an aggressive form of young-onset kidney cancer [17].

Ordinary fibroids, even if they grow quickly or occur in someone’s 30s, do not automatically mean a person has HLRCC or cancer [18]. However, you and your doctor should consider genetic counseling if your family history shows a suspicious pattern of “red flags,” such as:

  • Early-onset (often 20s or early 30s), unusually numerous, or large fibroids [19].
  • A personal or family history of cutaneous leiomyomas (often multiple, painful skin bumps) [17] [20].
  • A family history of kidney cancer, particularly at a young age [17].
  • Specific “FH-deficient” features found on pathology reports from previous fibroid surgeries [21].

What happens if HLRCC is suspected?
If a family shows this pattern, the first step is a referral for genetic counseling and targeted genetic testing, which can determine if an FH mutation is present [20] [21]. (Note that a person may warrant a genetics referral based on their own pathology, even without a known family history [21]).

If a pathogenic FH variant is confirmed in the family, at-risk relatives can be offered predictive testing [22]. Relatives who test positive (carriers) require lifelong, specialist-directed kidney surveillance—typically an annual MRI scan, as regular ultrasounds are not adequate for HLRCC surveillance [23] [24]. Relatives who test negative generally do not need this specialized kidney screening [22].

Ordinary Family History HLRCC Genetic Syndrome
Cause: Complex mix of genetics, hormones, and environment [6] Cause: Mutation in the FH gene [16]
Risk to Relatives: Increased likelihood of developing common fibroids [2] Risk to Relatives: Risk of multiple fibroids, painful skin bumps, and kidney cancer [17]
Action Needed: Routine preventive care; medical evaluation only if symptoms develop [3] Action Needed: Genetic counseling, targeted FH testing, and specialist-directed kidney MRIs for confirmed carriers [20] [23]

Common questions in this guide

If my mother or sister has fibroids, am I more likely to develop them?
Yes. Having a mother, sister, or daughter with fibroids raises your chance of developing them, but it does not mean you will definitely have them. Fibroids are common and usually result from a combination of inherited susceptibility, hormones, and environmental factors rather than one gene.
Should my symptom-free sister or daughter have an ultrasound for fibroids?
Usually not. Routine imaging is not recommended for relatives who feel well because silent fibroids often do not change medical care, while screening can lead to unnecessary tests and worry. Relatives should still keep their routine gynecologic visits and recommended preventive care.
What symptoms should prompt a relative to be evaluated for fibroids?
Medical evaluation is appropriate for heavy or prolonged periods, bleeding between periods, pelvic pressure or pain, lower-back pain, frequent urination, constipation, or difficulty becoming pregnant. Ongoing fatigue, dizziness, or weakness can signal anemia from heavy bleeding. Severe bleeding, fainting, shortness of breath, chest pain, sudden severe pelvic pain, bleeding during pregnancy, or bleeding after menopause requires urgent care.
When could a family pattern suggest HLRCC instead of common fibroids?
A rare condition called hereditary leiomyomatosis and renal cell cancer, or HLRCC, may be considered when a family has unusually early, numerous, or large fibroids along with painful skin bumps or kidney cancer at a young age. Ordinary fibroids alone, including fibroids that grow quickly or occur in the 30s, do not establish HLRCC. A genetics professional can review the family pattern.
What happens if genetic testing finds an FH mutation in my family?
Genetic counseling and targeted testing can determine which relatives carry the FH mutation. People who test positive need lifelong, specialist-directed kidney surveillance, typically with an annual MRI, while people who test negative generally do not need this specialized screening. The care team should set the surveillance schedule.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on uterine corpus leiomyoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my specific fibroid history (such as the age I was diagnosed, the number of tumors, or my pathology results) suggest I should consider a referral for genetic counseling?
  2. 2.Are there specific details about my fibroid diagnosis that I should share with my biological sisters or daughters?
  3. 3.If my daughter or sister begins experiencing heavy bleeding or pelvic pain, what evaluation is appropriate?
  4. 4.How can we determine if my fibroid symptoms or family history might be linked to HLRCC?

References

References (24)
  1. 1

    Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.

    Commandeur AE, Styer AK, Teixeira JM

    Human reproduction update 2015; (21(5)):593-615 doi:10.1093/humupd/dmv030.

    PMID: 26141720
  2. 2

    Assessing burden, risk factors, and perceived impact of uterine fibroids on women's lives in rural Haiti: implications for advancing a health equity agenda, a mixed methods study.

    Millien C, Manzi A, Katz AM, et al.

    International journal for equity in health 2021; (20(1)):1 doi:10.1186/s12939-020-01327-9.

    PMID: 33386078
  3. 3

    The management of uterine leiomyomas.

    Vilos GA, Allaire C, Laberge PY, et al.

    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2015; (37(2)):157-178 doi:10.1016/S1701-2163(15)30338-8.

    PMID: 25767949
  4. 4

    Clinical signs and diagnosis of fibroids from adolescence to menopause.

    Mension E, Carmona F, Vannuccini S, Chapron C

    Fertility and sterility 2024; (122(1)):12-19 doi:10.1016/j.fertnstert.2024.05.003.

    PMID: 38729337
  5. 5

    Current and Emerging Treatment Options for Uterine Fibroids.

    Ali M, Ciebiera M, Wlodarczyk M, et al.

    Drugs 2023; (83(18)):1649-1675 doi:10.1007/s40265-023-01958-6.

    PMID: 37922098
  6. 6

    MED12 mutations and fumarate hydratase inactivation in uterine adenomyomas.

    Heikkinen T, Äyräväinen A, Hänninen J, et al.

    Human reproduction open 2018; (2018(4)):hoy020 doi:10.1093/hropen/hoy020.

    PMID: 30895261
  7. 7

    Guideline No. 461: The Management of Uterine Fibroids.

    Chen I, Kives S, Randle E, et al.

    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2025; (47(8)):102970 doi:10.1016/j.jogc.2025.102970.

    PMID: 40562356
  8. 8

    Uterine Fibroids: Diagnosis and Treatment.

    De La Cruz MS, Buchanan EM

    American family physician 2017; (95(2)):100-107.

    PMID: 28084714
  9. 9

    A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma.

    Lewis TD, Malik M, Britten J, et al.

    BioMed research international 2018; (2018()):2414609 doi:10.1155/2018/2414609.

    PMID: 29780819
  10. 10

    Uterine disorders and iron deficiency anemia.

    Donnez J, Carmona F, Maitrot-Mantelet L, et al.

    Fertility and sterility 2022; (118(4)):615-624 doi:10.1016/j.fertnstert.2022.08.011.

    PMID: 36182260
  11. 11

    Diagnosis and management of uterine fibroids: current trends and future strategies.

    Ahmad A, Kumar M, Bhoi NR, et al.

    Journal of basic and clinical physiology and pharmacology 2023; (34(3)):291-310 doi:10.1515/jbcpp-2022-0219.

    PMID: 36989026
  12. 12

    Uterine fibroid management: from the present to the future.

    Donnez J, Dolmans MM

    Human reproduction update 2016; (22(6)):665-686 doi:10.1093/humupd/dmw023.

    PMID: 27466209
  13. 13

    Uterine Fibroids and Infertility.

    Freytag D, Günther V, Maass N, Alkatout I

    Diagnostics (Basel, Switzerland) 2021; (11(8)) doi:10.3390/diagnostics11081455.

    PMID: 34441389
  14. 14

    The management of uterine leiomyomas.

    Lefebvre G, Vilos G, Allaire C, et al.

    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2003; (25(5)):396-418; quiz 419-22.

    PMID: 12738981
  15. 15

    Diagnosis and classification of uterine fibroids.

    Lakabi R, Harth S, Meinhold-Heerlein I, et al.

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2025; (171(2)):566-573 doi:10.1002/ijgo.70538.

    PMID: 40970558
  16. 16

    [Hereditary leiomyomatosis and renal cell carcinoma syndrome : Pathological features, diagnostics, and clinical implications].

    Erber R, Hartmann A

    Pathologie (Heidelberg, Germany) 2026; (47(5)):360-369 doi:10.1007/s00292-026-01583-6.

    PMID: 42521857
  17. 17

    Fumarate hydratase-deficient uterine leiomyoma: A rare case report and literature review.

    Wang Q, Li Y, Shao Y, et al.

    Frontiers in oncology 2026; (16()):1854175 doi:10.3389/fonc.2026.1854175.

    PMID: 42421683
  18. 18

    Hereditary leiomyomatosis and renal cell carcinoma syndrome associated uterine smooth muscle tumors: Bridging morphology and clinical screening.

    Garg K, Rabban J

    Genes, chromosomes & cancer 2021; (60(3)):210-216 doi:10.1002/gcc.22905.

    PMID: 33099845
  19. 19

    Uterine leiomyomas in hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome can be identified through distinct clinical characteristics and typical morphology.

    Uimari O, Ahtikoski A, Kämpjärvi K, et al.

    Acta obstetricia et gynecologica Scandinavica 2021; (100(11)):2066-2075 doi:10.1111/aogs.14248.

    PMID: 34480341
  20. 20

    Hereditary Leiomyomatosis and Renal Cell Cancer in a Patient With Isolated Uterine Leiomyomas.

    Ardestani S, McGrattan M, Gillies B, et al.

    O&G open 2025; (2(1)):e058 doi:10.1097/og9.0000000000000058.

    PMID: 41000563
  21. 21

    Fumarate Hydratase-deficient Uterine Smooth Muscle Tumors: A 6-Year Prospective Analysis of Morphology-based Screening and Patient Outcomes.

    Sun T, Niu N, Healy C, et al.

    International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2026; (45(3)):189-199 doi:10.1097/PGP.0000000000001134.

    PMID: 40991420
  22. 22

    How a woman's myomectomy saved her father's life: evidence of fumarate hydratase-deficient uterine leiomyoma and early detection of germline variants in fumarate hydratase.

    Rivera-Cruz G, Boyraz B, Petrozza JC

    F&S reports 2022; (3(1)):26-31 doi:10.1016/j.xfre.2021.10.002.

    PMID: 35386501
  23. 23

    Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.

    Hol JA, Jongmans MCJ, Littooij AS, et al.

    Familial cancer 2020; (19(1)):55-63 doi:10.1007/s10689-019-00155-3.

    PMID: 31792767
  24. 24

    Hereditary leiomyomatosis and renal cell carcinoma: a case series and literature review.

    Chayed Z, Kristensen LK, Ousager LB, et al.

    Orphanet journal of rare diseases 2021; (16(1)):34 doi:10.1186/s13023-020-01653-9.

    PMID: 33461594

This page explains family risk and screening for uterine fibroids for informational purposes only and does not constitute medical advice. A gynecologist or genetic counselor can assess your symptoms and family history.